The consideration of the effectiveness of licorice root extract adding to triple therapy regime of Helicobacter Pylori

Comparison the eradication rate of Helicobacter pylori (HP) between standard triple therapy regime and licorice root extract adding to triple therapy regime in patients with helicobacter pylori infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014061718124N1

Enrollment

120

Registered

2015-06-21

Start date

2015-06-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori

Interventions

Intervention 1: Clarithromycin (500 mg twice a day) + Amoxicillin (1 gr twice a day) + Omeprazole (20 mg twice a day) for 2 weeks. After finishing the main period of treatment they receive maintaining

Treatment - Drugs

Clarithromycin (500 mg twice a day) + Amoxicillin (1 gr twice a day) + Omeprazole (20 mg twice a day) for 2 weeks. After finishing the main period of treatment they receive maintaining 4 weeks by omep

Intervention group: licorice root extracts ( D-Reglis 1 tab twice a day) adding to Clarithromycin (500 mg twice a day) + Amoxicillin (1 gr twice a day) + Omeprazole (20 mg twice a day) for 2 weeks. Af

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria to study: if all patients during endoscopic procedure with have positive rapid urease test (RUT), providing that not having the following condition: pregnancy? Previous usage Antiacid or bismuth during recent a month ? Gastrointestinal (GI) bleeding or any complication of peptic ulcer disease (PUD) ? the usage of alcohol or substance ? advanced chronic disease: Diabetes mellitus, Hypertension, Cirrhosis, Cerebrovascular attack, Coronary artery disease & gastric cancer. Exclusion criteria from study: lack of willingness to continue the treatment? lack of willingness to complete the period of treatment ?suffering the illness that needs to consume another antibiotic or non steroidal anti inflammatory drugs (NSAIDs) .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Stool antigen of HP. Timepoint: Two weeks after ending period of treatment. Method of measurement: Laboratoriaf.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sedighe Reisian

Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

ahmohammadi@qums.ac.ir; SRMDFM@gmail.com+98 28 3336 0084

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026